Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 25;158(6):251-259.
doi: 10.1016/j.medcli.2021.03.027. Epub 2021 May 7.

Susceptibility and risk of SARS-COV-2 infection among middle-aged and older adults in Tarragona area, Spain

[Article in English, Spanish]
Eva M Satué-Gracia  1 , Angel Vila-Córcoles  2 , Cinta de Diego-Cabanes  3 , Angel Vila-Rovira  4 , Cristina Torrente-Fraga  5 , Frederic Gómez-Bertomeu  6 , Imma Hospital-Guardiola  7 , Olga Ochoa-Gondar  8 , Francisco Martín-Luján  2
Affiliations

Susceptibility and risk of SARS-COV-2 infection among middle-aged and older adults in Tarragona area, Spain

[Article in English, Spanish]
Eva M Satué-Gracia et al. Med Clin (Barc). .

Abstract
in English, Spanish

Objective: To analyse susceptibility/risk of suffering COVID-19 among adults with distinct underlying medical conditions.

Methods: Population-based cohort study involving 79,083 individuals ≥50 years old in Tarragona (Southern Catalonia, Spain). Baseline cohort characteristics (demographic, pre-existing comorbidities, chronic medications and vaccinations history) were established at study start (01/03/2020) and primary outcome was laboratory-confirmed COVID-19 occurred among cohort members throughout 01/03/2020-30/06/2020. Risk of suffering COVID-19 was evaluated by Cox regression, estimating multivariable hazard ratios (HRs) adjusted for age/sex and pre-existing comorbidities.

Results: Across study period, 536 laboratory-confirmed COVID-19 cases were observed (mean incidence: 39.5 cases per 100,000 persons-week). In multivariable-analysis, increasing age/years (HR: 1.01; 95% CI: 1.00-1.02), nursing-home (HR: 20.19; 95% CI: 15.98-25.51), neurological disease (HR: 1.35; 95% CI: 1.03-1.77), taking diuretics (HR: 1.39; 95% CI: 1.10-1.75), antiplatelet (HR: 1.36; 95% CI: 1.05-1.76) and benzodiazepines (HR: 1.24; 95% CI: 1.00-1.53) increased risk; conversely, taking angiotensin-converting-enzyme inhibitors (HR: 0.78; 95% CI: 0.61-1.00), angiotensin-receptor-blockers (HR: 0.70; 95%CI: 0.51-0.96) and statins (HR: 0.75; 95% CI: 0.58-0.96) were associated with reduced risk. Among community-dwelling individuals, pre-existing cancer, renal and cardiac disease appeared also related with an increased risk, whereas influenza vaccination was associated with reduced risk.

Conclusion: In a setting with relatively low incidence of COVID-19 across the first wave of pandemic period, increasing age, nursing-home residence and multiple comorbidities appear predisposing for COVID-19 among middle-aged/older adults. Conversely, statins, angiotensin-receptor blockers/inhibitors and influenza vaccination were related with decreased risk.

Objetivo: Analizar incidencia y riesgo/susceptibilidad de sufrir la COVID-19 en adultos según distintas condiciones médicas preexistentes.

Métodos: Cohorte de base poblacional que incluyó 79.083 personas ≥50 años en Tarragona. Características basales de la cohorte (edad/sexo, comorbilidades, medicaciones crónicas) se establecieron a 01-03-2020 y se registraron todos los casos de COVID-19 confirmada ocurridos en miembros de la cohorte hasta el 30-06-2020. Para estimación de riesgos se realizó regresión de Cox, con cálculo de hazard ratio (HR) ajustados por edad, sexo y comorbilidad.

Resultados: Se observaron 536 casos confirmados de COVID-19 (incidencia media: 39,5 casos por 100.000 personas-semana). En análisis multivariante, edad/años (HR: 1,01; IC el 95%: 1,00-1,02; p = 0,050), estar institucionalizado/residencia (HR: 20,19; IC 95%: 15,98-25,51; p<0,001), enfermedad neurológica (HR: 1,35; IC el 95%: 1,03-1,77), diuréticos (HR: 1,39; IC 95%: 1,10-1,75), antiagregantes plaquetarios (HR: 1,36; IC 95%: 1,05-1,76) y benzodiacepinas (HR: 1,24; IC 95%: 1,00-1,53) se asociaron con un riesgo aumentado de la COVID-19 analizando la totalidad de la cohorte; contrariamente, medicación IECA (HR: 0,78; IC el 95%: 0,61-1,00), ARA-II (HR: 0,70; IC el 95%: 0,51-0,96) y estatinas (HR: 0,75; IC el 95%: 0,58-0,96) se asociaron con menor riesgo. Entre personas no institucionalizadas, cáncer, nefropatía y cardiopatía se asociaron con mayor riesgo y vacunación antigripal con menor riesgo.

Conclusión: En un área con relativamente baja incidencia de COVID-19, edad, institucionalización y múltiples comorbilidades aumentaron el riesgo/susceptibilidad de sufrir la COVID-19. Contrariamente, estatinas, inhibidores del sistema renina-angiotensina y vacunación antigripal se asociaron con menor riesgo.

Keywords: COVID-19; Coronavirus; Incidence; Incidencia; Riesgo; Risk; SARS-COV-2; SARS-CoV-2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study scheme. PCC: primary care centres; ICS: Institut Castalà de la Salut; e-CAP: electronic primary care clinical records system; ICD. International classification of diseases, 10th revision; ATC: Anatomic & Therapeutic Classification for medications used.
Fig. 2
Fig. 2
Weekly distribution of COVID-19-confirmed cases across study period (March 1st–June 30th 2020).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. World Health Organisation (WHO). Listings of WHO's response to COVID-19. Available from: https://www.who.int/news/item/29-06-2020-covidtimeline [accessed 20.1.21].
    1. World Health Organisation (WHO). Coronavirus Disease (COVID19). Weekly epidemiological update-27 January 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update---... [accessed 28.1.21].
    1. Ministerio de Sanidad. Dirección General de Salud Pública. Centro de Coordinación de Alertas y Emergencias Sanitarias. Actualización n(300. Enfermedad por el coronavirus (COVID-19). 28.01.2021. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual... [accessed 28.1.21].
    1. Rodríguez-Molinero A., Gálvez-Barrón C., Miñarro A., Macho O., López G.F., Robles M.T., et al. COVID-19 Research Group of CSAPG Association between COVID-19 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized patients. PLOS ONE. 2020;15:e0239571. doi: 10.1371/journal.pone.0239571. - DOI - PMC - PubMed
    1. Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Castelli A., et al. COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574–1581. doi: 10.1001/jama.2020.5394. - DOI - PMC - PubMed